tavolixizumab (MEDI0562)

News alerts, weekly reports and conference planners

Company:

AstraZeneca

Drug class:

OX40 agonist

Related drugs:

2years

Safety and tolerability of MEDI0562, an OX40 agonist monoclonal antibody, in combination with durvalumab or tremelimumab in adult patients with advanced solid tumors. (PubMed, Clin Cancer Res)

Following dose escalation, moderate toxicity was observed in both treatment arms, with no clear efficacy signals demonstrated.

2 years ago

Journal • Combination therapy

CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)

Imfinzi (durvalumab) • Imjudo (tremelimumab) • tavolixizumab (MEDI0562)

4years

Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients With Advanced Solid Tumors. (PubMed, Clin Cancer Res)

MEDI0562 was safely administered at doses up to 10 mg/kg in heavily pre-treated patients. On-target pharmacodynamic effects were suggested in this setting. Further evaluation with immune checkpoint inhibitors is ongoing.

4 years ago

Clinical • Journal

FOXP3 (Forkhead Box P3)

tavolixizumab (MEDI0562)

over4years

[VIRTUAL] Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors. (ASCO 2020)

Background: We report safety and tolerability of MEDI0562, a humanized IgG1κ OX40 monoclonal antibody (mAb), in combination with durvalumab (durva; anti-PD-L1 mAb) or tremelimumab (treme; anti-CTLA-4 mAb) in patients (pts) with previously treated advanced solid tumors. The safety profile of MEDI0562 in combination with durva or treme was similar between groups. Clinical activity was observed with MEDI0562 + durva in pts with advanced solid tumors. Research Funding: AstraZeneca

over 4 years ago

Clinical • Combination therapy

TNFRSF4 (TNF Receptor Superfamily Member 4)

Imfinzi (durvalumab) • Imjudo (tremelimumab) • tavolixizumab (MEDI0562)